Experience

Meditech Media

• Pharmaceutical Manufacturing
• 100 - 200 Employee

• Senior Medical Writer

  • Jan 2022 - Present

• Medical writer II

  • Aug 2020 - Present



University of California, San Francisco

• United States
• Higher Education
• 700 & Above Employee

• Post-doctoral Fellow

  • Aug 2014 - Aug 2020

  Researched, planned, and executed experiments for all of my research projects. I have 3 first author research publication, 3 first author review articles.I have mentored 2 internship students.I regularly present my research at public seminars and yearly at national conferences.“Euphorbia Kansui reactivates latent HIV”“Procyanidin Trimer C1 reactivates latent HIV as a triple combination therapy with kansui and JQ1”Identified two compounds derived which potently reactivate latent HIV in cell line, primary CD4+ T cell models of latency, as well as HIV+ patient derived PBMC. Determined that combination therapy, including compounds which activate latent HIV through different mechanisms, results in reduced effective concentrations. Optimized a CD4+ T cell model to study HIV latency.Maintained contact with a clinical researchers at the outset of kansui studies, to advocate for the clinical application of kansui. Kansui was tested in NHP and is currently enrolling for a small clinical trial. “HIV transcription is independent of mediator kinases”Determined that mediator kinases are dispensible for HIV transcription using a combination of knockdowns and chemical inhibitors. “Mechanisms regulating Cyclin T1 expression in CD4+ T cells”Examined the mechanisms which regulate Cyclin T1 expression in resting CD4+ T cells, which contributes to maintenance and reactivation of latent HIV. Both endogenous expression in human primary CD4+ T cells and mutagenesis and overexpression in permissive cell lines were used to determine how Cyclin T1 expression is regulated.Informed by these mechanisms, I’ve identified a proteasomal inhibitor, which is approved for treatment of multiple myeloma, as a potential novel HIV latency reversing agent, which may also inhibit HIV accessory protein expression.Leadership and Service2018 CFAR Early Stage Investigator Leadership Retreat2018 The Andy I. Choi Mentoring Program of the UCSF-Gladstone Center for AIDS Research



Boston University School of Medicine

• United States
• Higher Education
• 700 & Above Employee

• Graduate Research Assistant

  • Aug 2007 - Jul 2014

  “RON receptor tyrosine kinase, a negative regulator of inflammation, is decreased during simian immunodeficiency virus associated central nervous system disease”Determined the role of the receptor tyrosine kinase RON in SIV associated CNS disease. Studied the molecular mechanisms by which RON activity regulates inflammatory and anti-inflammatory mediators. Developed an in vitro model of tissue resident macrophages using human tonsil tissue. “RON receptor tyrosine kinase, a negative regulator of inflammation, is decreased during simian immunodeficiency virus associated central nervous system disease”Determined the role of the receptor tyrosine kinase RON in SIV associated CNS disease. Studied the molecular mechanisms by which RON activity regulates inflammatory and anti-inflammatory mediators. Developed an in vitro model of tissue resident macrophages using human tonsil tissue.



Purdue University

• United States
• Higher Education
• 700 & Above Employee

• Graduate Research Assistant

  • Aug 2003 - Jul 2005

  “Modulation of immune function of neonatal dairy calves fed a yeast cell-wall product with ascorbyl-2 polyphosphate” “Modulation of immune function of neonatal dairy calves fed a yeast cell-wall product with ascorbyl-2 polyphosphate”



University of Pittsburgh Cancer Institute

• Research Technician III

  • 1998 - 2003